Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Summary not available.
Lantern Pharma (NASDAQ: LTRN) announced the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application related to its drug candidate LP-284, targeting non-Hodgkin's lymphomas. This patent is expected to provide market exclusivity until 2039. The company plans to submit an Investigational New Drug (IND) application for LP-284 to the FDA in mid-2023 and commence a Phase 1 clinical trial later this year. LP-284, with nanomolar potency, addresses significant unmet needs among patients with mantle cell lymphoma (MCL) and double-hit lymphoma (DHL), presenting an estimated annual market potential of $1.2 billion. The candidate has also received Orphan Drug Designation from the FDA for MCL, enhancing its development pathway.
Lantern Pharma Inc. (NASDAQ: LTRN) has initiated the Phase 2 Harmonic™ clinical trial, dosing the first patient with its investigational drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer (NSCLC). The trial aims to assess the overall and progression-free survival in 90 patients, with 60 receiving LP-300 and 30 on standard chemotherapy. Previous trials showed a 91% overall survival rate at two years for LP-300 patients compared to those on chemotherapy alone. The market potential for this demographic is estimated between $1.5 to $2.0 billion.
Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company utilizing its RADR® AI platform for oncology drug development, announced presentations at three upcoming events. CEO Panna Sharma will present on March 22 at the Rare Disease Innovation & Partnership Summit in Philadelphia, discussing AI in drug development. He will also participate in a free webinar on March 23, co-hosted by Science History Institute and American Chemical Society, focusing on AI's impact on drug discovery. Additionally, Peter Carr will moderate a session at the Genomics in Precision Oncology Xchange on April 5 in Boston, emphasizing clinical trial design.
For more information, visit www.lanternpharma.com.
Lantern Pharma (NASDAQ: LTRN) announced significant operational highlights and financial results for the fourth quarter and fiscal year 2022. The Harmonic™ clinical trial for never-smoker patients with non-small cell lung cancer (NSCLC) has activated 5 clinical sites across 12 locations, with patient enrollment expected in Q2 2023. The company also completed IND-enabling studies for drug candidates LP-184 and LP-284, with IND submissions planned for April and mid-2023, respectively. Lantern reported a cash position of $55.2 million as of December 31, 2022, and expects a cash runway into 2025. The formation of Starlight Therapeutics for CNS cancer treatments was also highlighted.
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in the AACR Annual Meeting from April 14-19, 2023 in Orlando, FL. The company will present a poster titled LP-184, an acylfulvene class small molecule therapeutic, focusing on its synthetic lethality mechanism targeting DNA damage repair deficient cancers, affecting 25-30% of solid tumors. The presentation is scheduled for April 19, 2023, 9:00 a.m. – 12:30 p.m. ET. Lantern aims to advance LP-184 to a Phase 1 clinical trial by mid-2023. Additionally, a webinar on synthetic lethality will be held on March 21, 2023 featuring expert Zoltan Szallasi.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a webcast on March 20, 2023, at 4:30 p.m. ET, to disclose its fourth quarter and fiscal year 2022 financial results. Management, led by CEO Panna Sharma, will discuss operating and financial metrics for the fiscal year ended December 31, 2022 and outline upcoming milestones. Lantern Pharma is focused on oncology and leverages its proprietary RADR® AI platform to enhance drug discovery methods.
A replay will be available post-call on their investor relations website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced that it has no exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank, ensuring its financial stability. The company’s cash, cash equivalents, and marketable securities are managed through top-tier financial institutions, providing sufficient resources to support operations and development through 2025. Lantern Pharma utilizes its proprietary RADR® AI platform to enhance oncology drug discovery, focusing on genomic profiling to identify patients likely to benefit from its therapeutics. This strategic approach aims to improve treatment outcomes for cancer patients.
Lantern Pharma (NASDAQ: LTRN) announced new findings supporting the development of LP-100 combined with PARP inhibitors for treating metastatic prostate cancer and other indications. Synergistic effects were observed in studies using LP-100 alongside notable PARP agents like Olaparib. Preliminary Phase 2 trial data indicated a median overall survival of 12.5 months for nine patients in Denmark, better than comparable treatment regimens. Future market potential for LP-100 is estimated between $700 million and $2 billion. This strategic focus aims to maximize LP-100's market opportunities while enhancing treatment pathways for patients with specific gene mutations.
Lantern Pharma (NASDAQ: LTRN) will host a virtual key opinion leader (KOL) webinar on March 21, 2023, at 12:00 p.m. ET, focusing on synthetic lethality in oncology. Dr. Zoltan Szallasi, a prominent expert, will discuss the mechanism of action behind Lantern's drug candidate LP-184 and its implications for solid tumors. Attendees will learn about the history of synthetic lethality, how it targets DNA damage repair deficiencies, and LP-184's potential to enhance cancer treatments. Registration is available here. A replay will be accessible on Lantern's website following the event.